1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Diagnostics & Research
NeoGenomics, Inc.

NeoGenomics, Inc.

NEO
NeoGenomics, Inc.US flagNASDAQ Capital Market
15.29
USD
-0.59
- -
392.88MMarket Cap

Total Valuation

NeoGenomics, Inc. carries a market capitalization of 392.88M, placing it among publicly traded companies globally. Its enterprise value stands at 2.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap392.88M
Enterprise Value2.17B

Share Statistics

NeoGenomics, Inc. currently has 127.92M shares outstanding.

Shares Outstanding127.92M
Owned by Insiders (%)N/A
Owned by Institutions (%)N/A

Valuation Ratios

The price-to-sales ratio is 2.46, and the price-to-book ratio stands at 2.38.

PE RatioN/A
PS Ratio2.46
PB Ratio2.38
P/TBV Ratio-195.94
P/FCF Ratio36.65
P/OCF Ratio85.34

Enterprise Valuation

On an enterprise value basis, NeoGenomics, Inc. trades at an EV/EBITDA multiple of 458.89 and an EV/FCF ratio of 40.24.

EV / Sales2.83
EV / EBITDA458.89
EV / EBITN/A
EV / FCF40.24

Financial Position

NeoGenomics, Inc. maintains a current ratio of 3.60, meaning it holds 3.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 57.06, indicating elevated leverage, while an interest coverage ratio of 1.83 demonstrates limited ability to service its debt obligations.

Current Ratio3.60
Quick Ratio3.03
Debt / Equity57.06
Debt / EBITDA94.85
Interest Coverage1.83

Financial Efficiency

Return on Equity (ROE)-6.33
Return on Assets (ROA)-3.78
Return on Invested Capital (ROIC)N/A
Return on Capital Employed (ROCE)N/A
Revenue Per EmployeeN/A
Employee CountN/A
Inventory Turnover14.02

Taxes

Income Tax-2.67M
Effective Tax RateN/A

Stock Price Statistics

NeoGenomics, Inc.'s stock has gained approximately 196.31783% over the past 52 weeks. The 50-day moving average sits at 12.61, while the 200-day moving average is 10.84.

Beta (5Y)N/A
52-Week Price Change196.31783%
50-Day Moving Average12.61
200-Day Moving Average10.84
Average Volume (20 Days)N/A

Income Statement

Over the trailing twelve months, NeoGenomics, Inc. generated 766.30M in revenue and converted that into -51.88M in net income, yielding earnings per share of -0.40. EBITDA reached 4.73M, while operating income came in at -60.73M.

Revenue766.30M
Gross Profit336.53M
Operating Income-60.73M
Pretax Income-54.55M
Net Income-51.88M
EBITDA4.73M
EBIT-60.73M
Earnings Per Share (EPS)-0.40

Balance Sheet

NeoGenomics, Inc. holds 145.54M in cash and equivalents against 448.37M in total debt, resulting in a net debt position of 228.70M. Total book value stands at 785.73M, with working capital of 275.60M providing operational flexibility.

Cash & Cash Equivalents145.54M
Total Debt448.37M
Net Debt228.70M
Equity (Book Value)785.73M
Book Value Per Share6.14
Working Capital275.60M

Cash Flow

NeoGenomics, Inc. produced 22.05M in operating cash flow over the past twelve months. After subtracting -29.40M in capital expenditures, free cash flow totaled -7.35M - equivalent to -0.06 per share.

Operating Cash Flow22.05M
Capital Expenditures-29.40M
Free Cash Flow-7.35M
FCF Per Share-0.06

Margins

NeoGenomics, Inc. operates with a gross margin of 43.92, reflecting its pricing power and cost economics. The operating margin of -7.92 and net profit margin of -6.77 provide insight into operational efficiency.

Gross Margin43.92
Operating Margin-7.92
Pretax Margin-7.12
Profit Margin-6.77
EBITDA Margin0.62

Dividends & Yields

Dividend Per ShareN/A
Dividend YieldN/A
Payout RatioN/A
Shareholder Yield0.61
FCF Yield2.73

Stock Splits

NeoGenomics, Inc.'s most recent stock split took place on April 16, 2003 with a 100:1 split ratio.

Last Split Date4/16/2003
Split Ratio100:1

Scores

NeoGenomics, Inc. posts an Altman Z-Score of 2.46, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score2.46